All published articles of this journal are available on ScienceDirect.
The Journey for Lung Cancer Screening where we Stand Today
Zaid Zoumot1
Mateen Uzbeck1
Jihad Mallat1
Redha Souilamas1
Irfan Shafiq1
Authors Info & Affiliations
Abstract
Background:
Lung cancer remains a leading cause of cancer mortality worldwide with many patients presenting with advanced disease.
Objective:
We reviewed the available literature for lung cancer screening using low dose computed tomography (LDCT). We reviewed the National Lung Screening Trial (NLST), Early Lung Cancer Action Program (ELCAP) and the (Nederlands–Leuvens Longkanker Screenings Onderzoek (NELSON) trials. We also look at different lung cancer risk prediction models that may aid in identifying target populations and also discuss the cost-effectiveness of LDCT screening in different groups of smokers and ex-smokers. Lastly, we discuss recent guideline changes that have occurred in line with new and emerging evidence on lung cancer screening.
Conclusion:
LDCT has been shown reduce lung cancer mortality in certain groups of current and former smokers and should be considered to help in the early diagnosis of lung cancer.
